var data={"title":"Pioglitazone: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pioglitazone: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6782?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pioglitazone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pioglitazone: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709212\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Congestive heart failure:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Thiazolidinediones, including pioglitazone, can cause or exacerbate congestive heart failure (CHF) in some patients. After initiation of pioglitazone, and after dose increases, observe patients carefully for signs and symptoms of heart failure (including excessive, rapid weight gain, dyspnea, and/or edema). If these signs and symptoms develop, manage the heart failure according to the current standards of care. Furthermore, discontinuation or dose reduction of pioglitazone must be considered.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Pioglitazone is not recommended in patients with symptomatic heart failure. Initiation of pioglitazone in patients with established New York Heart Association (NYHA) class III or IV heart failure is contraindicated.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210230\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Actos</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50663870\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Actos</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210256\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidiabetic Agent, Thiazolidinedione</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210234\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Diabetes mellitus, type 2: </b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Initial:</b> 15 to 30 mg once daily; patients with heart failure (NYHA Class I or II) should initiate therapy with 15 mg once daily. <b>Note:</b> Not recommended in patients with symptomatic heart failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage titration:</b> Based on HbA<sub>1c</sub>, the dosage may be increased in 15 mg increments up to a maximum of 45 mg once daily;  monitor closely during titration for adverse effects (eg, weight gain, edema, signs/symptoms of heart failure)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment for hypoglycemia with combination therapy:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>With an insulin secretagogue (eg, sulfonylurea):</i> Decrease the insulin secretagogue dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>With insulin:</i> Decrease insulin dose by 10% to 25%; individualize further adjustments per glycemic response</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment with strong CYP2C8 inhibitors (eg, gemfibrozil):</b> Maximum recommended dose: 15 mg once daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210235\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210236\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment  necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210237\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic impairment prior to initiation: No dosage adjustment necessary; use with caution if baseline liver tests are abnormal</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic impairment during therapy: If liver injury is suspected (eg, fatigue, jaundice, dark urine): Interrupt therapy, measure serum liver tests, and investigate possible etiologies:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If an alternative etiology is not identified and ALT &gt;3 x ULN: Do not reinitiate therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If an alternative etiology is identified and ALT elevated (but &lt;3 x ULN) <b>or</b> total bilirubin elevated (but &lt;2 x ULN): May reinitiate with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210208\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Actos: 15 mg, 30 mg, 45 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 15 mg, 30 mg, 45 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210194\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9350995\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021073s049lbl.pdf#page=35&amp;token=wXz3OMCq4EBwQEC+je2+723VcOlg7iIO2d58exHXUHjSf9m39n5WE2ygTHsH/OYxom8ADUkxQhG6fTxwb0sNnhWOGhB8/IUUphV+xBSTvwbSTu9/xHjnsVFvh1lOl1Kf&amp;TOPIC_ID=10216\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021073s049lbl.pdf#page=35</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210210\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: May be administered without regard to meals</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210209\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Diabetes mellitus, type 2: </b> As an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210263\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Actos may be confused with Actidose, Actonel</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Tiazac: Brand name for pioglitazone [Chile], but also the brand name for dilTIAZem [U.S, Canada]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210201\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse reactions and incidences reported are associated with monotherapy unless otherwise stated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Edema (combination trials: &le;27%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine and metabolic: Hypoglycemia (combination trials: &le;27%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Cardiac failure (combination trials: &le;8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Bone fracture (females: &le;5%), myalgia (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Sinusitis (6%), pharyngitis (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Decreased serum triglycerides, increased HDL-cholesterol, weight gain, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Decreased hematocrit, decreased hemoglobin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Bladder carcinoma, blurred vision, decreased visual acuity, dyspnea (associated with weight gain and/or edema), hepatic failure (very rare), hepatitis, increased creatine phosphokinase, increased serum transaminases, macular edema (new-onset or worsening), pulmonary edema, rhabdomyolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210213\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to pioglitazone or any component of the formulation; NYHA Class III/IV heart failure (initiation of therapy)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Canadian labeling: Additional contraindications (not is U.S. labeling): Any stage of heart failure (eg, NYHA Class I, II, III, IV); serious hepatic impairment; active bladder cancer; history of bladder cancer; uninvestigated macroscopic hematuria; pregnancy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210198\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bladder cancer: An FDA review concluded that although clinical trial data are inconsistent regarding the risk of bladder cancer in patients exposed to pioglitazone, there is still the potential for an increased risk and package labeling has been updated to reflect this. Avoid use of pioglitazone in patients with active bladder cancer and consider risks versus benefits prior to initiating therapy in patients with a history of bladder cancer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Edema: Dose-related edema, including new-onset or exacerbation of existing edema, has been reported; use with caution in patients with edema. Monitor for signs/symptoms of heart failure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fractures: An increased incidence of bone fractures in females treated with pioglitazone has been observed; majority of fractures occurred in the lower limb and distal upper limb. Consider risk of fracture prior to initiation and during use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure/cardiac effects: <b>[US Boxed Warning]: Thiazolidinediones, including pioglitazone, may cause or exacerbate heart failure; closely monitor for signs and symptoms of heart failure (eg, rapid weight gain, dyspnea, edema), particularly after initiation or dose increases; if heart failure develops, treat accordingly and consider dose reduction or discontinuation of pioglitazone. Not recommended for use in any patient with symptomatic heart failure. Initiation of therapy is contraindicated in patients with NYHA class III or IV heart failure;</b> if used in patients with NYHA class I or II (systolic) heart failure, initiate at lowest dosage and monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: May decrease hemoglobin/hematocrit; effects may be related to increased plasma volume.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Hepatic failure, including fatalities, has been reported. Monitor for signs/symptoms of liver injury closely during therapy; discontinuation of therapy may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypoglycemia: The risk of hypoglycemia is increased when pioglitazone is combined with insulin or other diabetic medications; dosage adjustment of concomitant hypoglycemic agents may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Macular edema: Has been reported with thiazolidinedione use, including pioglitazone; some patients with macular edema presented with blurred vision or decreased visual acuity, and most had peripheral edema at time of diagnosis. Patients should be seen by an ophthalmologist if any visual symptoms arise during therapy and all diabetic patients should have regular eye exams.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Weight gain: Dose-related weight gain observed with use; mechanism unknown but likely associated with fluid retention and fat accumulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes, type 1: Mechanism requires the presence of insulin; therefore, use in type 1 diabetes (insulin dependent, IDDM) or diabetic ketoacidosis is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Due to the possible risk of drug-induced liver injury, serum liver function tests (ALT, AST, alkaline phosphatase, and total bilirubin) should be obtained prior to initiation in all patients. In patients with abnormal hepatic tests, therapy should be initiated with caution. During therapy, if signs/symptoms of liver injury (eg, fatigue, anorexia, jaundice, dark urine, right upper abdominal discomfort) arise, interrupt pioglitazone therapy, obtain liver tests immediately and evaluate alternative etiologies. If an alternative etiology is not identified and serum ALT is &gt;3 &times; ULN, do not resume therapy. Patients with serum ALT &gt;3 &times; ULN and serum total bilirubin &gt;2 &times; ULN are at risk for severe drug-induced liver injury.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210250\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2C8 (major), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210203\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10216&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP2C8 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Androgens: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<b> Exceptions: </b>Danazol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clopidogrel: May increase the serum concentration of Pioglitazone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C8 Inhibitors (Moderate): May decrease the metabolism of CYP2C8 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C8 Inhibitors (Strong): May increase the serum concentration of Pioglitazone. Management: Limit pioglitazone adult maximum dose to 15 mg/day when used in combination with any strong CYP2C8 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP2C8 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP2C8 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May increase the serum concentration of CYP2C8 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gemfibrozil: May decrease the metabolism of Thiazolidinediones. Management: Limit pioglitazone maximum adult dose to 15 mg/day, and consider dose reduction of rosiglitazone, when used in combination with gemfibrozil.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Insulins: Pioglitazone may enhance the adverse/toxic effect of Insulins. Specifically, the risk for hypoglycemia, fluid retention, and heart failure may be increased with this combination.  Management: If insulin is combined with pioglitazone, dose reductions should be considered to reduce the risk of hypoglycemia. Monitor patients for fluid retention and signs/symptoms of heart failure.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May increase the serum concentration of CYP2C8 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor may decrease the serum concentration of CYP2C8 Substrates (High Risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP2C8 Substrates (High risk with Inhibitors). Management: Use CYP2C8 substrates at the lowest recommended dose, and monitor closely for adverse effects (including myopathy), during and in the 2 weeks following mifepristone treatment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pregabalin: May enhance the fluid-retaining effect of Thiazolidinediones.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prothionamide: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May increase the metabolism of Thiazolidinediones. Management: Consider alternatives to the concomitant use of rifampin with thiazolidinedione antidiabetic agents.  Monitor patients receiving these combinations for decreased effects of the thiazolidinedione derivative.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonylureas: Thiazolidinediones may enhance the hypoglycemic effect of Sulfonylureas.  Management: Consider sulfonylurea dose adjustments in patients taking thiazolidinediones and monitor for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: May decrease the serum concentration of Pioglitazone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimethoprim: May decrease the metabolism of Thiazolidinediones.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210215\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Information related to the use of pioglitazone in pregnant women is limited (Glueck 2003; Ortega-Gonzalez 2005; Ota 2008). Thiazolidinediones may cause ovulation in anovulatory premenopausal women, increasing the risk of unintended pregnancy.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In women with diabetes, maternal hyperglycemia can be associated with congenital malformations as well as adverse effects in the fetus, neonate, and the mother (ACOG 2005; ADA 2018c; Kitzmiller 2008; Metzger 2007). To prevent adverse outcomes, prior to conception and throughout pregnancy maternal blood glucose and HbA<sub>1c</sub> should be kept as close to target goals as possible but without causing significant hypoglycemia (ACOG 2013; ADA 2018c; Blumer 2013; Kitzmiller 2008).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Agents other than pioglitazone are currently recommended to treat diabetes in pregnant women (ADA 2018c).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210216\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if pioglitazone is excreted in breast milk. Although breastfeeding is encouraged for all women, including those with diabetes, the safety of pioglitazone during breastfeeding has not yet been established (Metzger 2007). According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210217\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Individualized medical nutrition therapy (MNT) is an integral part of therapy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210206\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemoglobin A<sub>1c</sub> (at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; quarterly in patients not meeting treatment goals or with therapy change [ADA 2018a]), serum glucose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Liver enzymes (ALT, AST, alkaline phosphatase, and total bilirubin) prior to initiation in all patients (with or without liver disease); continue routine periodic monitoring during treatment only in patients with liver disease or suspected liver disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Signs and symptoms of fluid retention or heart failure; weight gain; signs/symptoms of bladder cancer (dysuria, macroscopic hematuria, dysuria, urinary urgency); ophthalmic exams</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6258749\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Recommendations for glycemic control in nonpregnant adults with diabetes (ADA 2018a):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HbA<sub>1c</sub>: &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] HbA<sub>1c</sub> goal may be targeted based on patient-specific characteristics)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preprandial capillary blood glucose: 80 to 130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak postprandial capillary blood glucose: &lt;180 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Recommendations for glycemic control in older adults (&ge;65 years) with diabetes (ADA 2018b):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HbA<sub>1c</sub>: &lt;7.5% (healthy); &lt;8% (complex/intermediate health); &lt;8.5% (very complex/poor health) (individualization may be appropriate based on patient and caregiver preferences)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preprandial capillary blood glucose: 90 to 130 mg/dL (healthy); 90 to 150 mg/dL (complex/intermediate health); 100 to 180 mg/dL (very complex/poor health)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bedtime capillary blood glucose: 90 to 150 mg/dL (healthy); 100 to 180 mg/dL (complex/intermediate health); 110 to 200 mg/dL (very complex/poor health)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210197\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Thiazolidinedione antidiabetic agent that lowers blood glucose by improving target cell response to insulin, without increasing pancreatic insulin secretion. It has a mechanism of action that is dependent on the presence of insulin for activity. Pioglitazone is a potent and selective agonist for peroxisome proliferator-activated receptor-gamma (PPARgamma). Activation of nuclear PPARgamma receptors influences the production of a number of gene products involved in glucose and lipid metabolism. PPARgamma is abundant in the cells within the renal collecting tubules; fluid retention results from stimulation by thiazolidinediones which increases sodium reabsorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210212\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Delayed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak effect: Glucose control: Several weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub> (apparent): 0.63 &plusmn; 0.41 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Pioglitazone &gt;99% and active metabolites &gt;98%; primarily to albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic (99%) via CYP2C8 and 3A4 to active and inactive metabolites; M-III and M-IV are major circulating active metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Parent drug: 3 to 7 hours; M-III and M-IV metabolites: 16 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: ~2 hours; delayed with food</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (15% to 30%) and feces as metabolites</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210214\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Actos Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (30): $466.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (30): $712.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">45 mg (30): $772.91</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Pioglitazone HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (30): $210.17</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (30): $321.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">45 mg (30): $348.39</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210218\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acpio (AU);</li>\n      <li>Acstin (KR);</li>\n      <li>Actos (AE, AR, AT, AU, BB, BE, BG, BH, BM, BO, BR, BS, BZ, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EE, ES, FI, FR, GB, GR, GT, GY, HK, HN, HR, HU, ID, IE, IL, IT, JM, JO, JP, KR, KW, LB, LT, LU, LV, MT, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PR, PT, QA, RO, RU, SA, SE, SG, SI, SK, SR, SV, TH, TR, TT, TW, VE);</li>\n      <li>Actozon (KR);</li>\n      <li>Anxotos (TW);</li>\n      <li>Apogar (MX);</li>\n      <li>Cereluc (AR);</li>\n      <li>Deculin (ID);</li>\n      <li>Diabetone (PH);</li>\n      <li>Diaglit (BD);</li>\n      <li>DMZone (KR);</li>\n      <li>Gitazone (TH);</li>\n      <li>Glados (QA);</li>\n      <li>Glezone (KR);</li>\n      <li>Gliabetes (ID);</li>\n      <li>Glidipion (IE, RO);</li>\n      <li>Gliozac (MX);</li>\n      <li>Glita (IN);</li>\n      <li>Glitaz (ET, PH);</li>\n      <li>Glitis (TW);</li>\n      <li>Glito (LK, VN);</li>\n      <li>Glitter (PH);</li>\n      <li>Glizone (KR);</li>\n      <li>Glubosil (TH);</li>\n      <li>Glucemin (CO);</li>\n      <li>Gluconon (KR);</li>\n      <li>Glustin (AE, AT, BE, BF, BG, BH, BJ, CH, CI, CY, CZ, DE, DK, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, HN, HU, IE, IL, IQ, IR, IT, KE, KW, LB, LR, LT, LY, MA, ML, MR, MT, MU, MW, NE, NG, NL, NO, OM, PT, QA, RU, SA, SC, SD, SE, SK, SL, SN, SY, TN, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Hlyutazon (UA);</li>\n      <li>Insulact (PH);</li>\n      <li>Insulact Forte (PH);</li>\n      <li>Kai Bao Wei Yuan (CN);</li>\n      <li>Lispecip (RO);</li>\n      <li>Newpio (KR);</li>\n      <li>Nilgar (VN);</li>\n      <li>Ogli (BD);</li>\n      <li>Paglitaz (IE);</li>\n      <li>Pidus (BD);</li>\n      <li>Pio (HR);</li>\n      <li>Pioglit (IN, PY);</li>\n      <li>Pioglite (VN);</li>\n      <li>Piolidone (KR);</li>\n      <li>Piomed (UY);</li>\n      <li>Piomin (KR);</li>\n      <li>Pionix (ID);</li>\n      <li>Piosafe 15 (TZ);</li>\n      <li>Piosugar (TW);</li>\n      <li>Piota (TW);</li>\n      <li>Piouno (PH);</li>\n      <li>Piozer (LK);</li>\n      <li>Piozon (BD);</li>\n      <li>Piozone (PH, TH);</li>\n      <li>Pizaccord (AU);</li>\n      <li>Politone (TW);</li>\n      <li>Ppar (PH);</li>\n      <li>Prabetic (ID);</li>\n      <li>Prialta (PH);</li>\n      <li>Protaz (ID);</li>\n      <li>Relexil (MX);</li>\n      <li>Senzulin (TH);</li>\n      <li>Uniglit (JO);</li>\n      <li>Utmos (TH);</li>\n      <li>Vexazone (AU);</li>\n      <li>Zactos (MX);</li>\n      <li>Zolid (PK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Actos (pioglitazone) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Actos (pioglitazone) [product monograph]. Oakville, Ontario, Canada: Takeda Canada Inc; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists, &quot;ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 60, March 2005. Pregestational Diabetes Mellitus,&quot; <i>Obstet Gynecol</i>, 2005, 105(3):675-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/15738045/pubmed\" target=\"_blank\" id=\"15738045\">15738045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG), Committee on Practice Bulletins&mdash;Obstetrics. Practice Bulletin No. 137: Gestational diabetes mellitus. <i>Obstet Gynecol</i>. 2013;122(2 Pt 1):406-416.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/23969827/pubmed\" target=\"_blank\" id=\"23969827\">23969827</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"29222377\"></a>American Diabetes Association (ADA). 6. Glycemic targets: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018;41(suppl 1):S55-S64. doi: 10.2337/dc18-S006.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/29222377/pubmed\" target=\"_blank\" id=\"29222377\">29222377</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"29222382\"></a>American Diabetes Association (ADA). 11. Older adults: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018;41(suppl 1):S119-S125. doi: 10.2337/dc18-S011.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/29222382/pubmed\" target=\"_blank\" id=\"29222382\">29222382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 13. Management of diabetes in pregnancy: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018c;41(suppl 1):S137-S143. doi: 10.2337/dc18-S013.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/29222384/pubmed\" target=\"_blank\" id=\"29222384\">29222384</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2013;98(11):4227-4249.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/24194617 /pubmed\" target=\"_blank\" id=\"24194617 \">24194617 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, &quot;Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada,&quot; <i>Can J Diabetes</i>, 2013, 35(Suppl 1):1-212.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dormandy JA, Charbonnel B, Eckland DJ, et al, &ldquo;Secondary Prevention of Macrovascular Events in Patients With Type 2 Diabetes in the PROactive Study (PROspective PioglitAzone Clinical Trial In MacroVascular Events): A Randomised Controlled Trial,&rdquo; <i>Lancet</i>, 2005, 366(9493):1279-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/16214598/pubmed\" target=\"_blank\" id=\"16214598\">16214598</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fauser BC, Tarlatzis BC, Rebar RW, et al, &quot;Consensus on Women's Health Aspects of Polycystic Ovary Syndrome (PCOS): The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group,&quot; <i>Fertil Steril</i>, 2012, 97(1):28-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/22153789/pubmed\" target=\"_blank\" id=\"22153789\">22153789</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glueck CJ, Moreira A, Goldenberg N, et al, &quot;Pioglitazone and Metformin in Obese Women With Polycystic Ovary Syndrome Not Optimally Responsive to Metformin,&quot; <i>Hum Reprod</i>, 2003, 18(8):1618-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/12871871/pubmed\" target=\"_blank\" id=\"12871871\">12871871</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Handelsman Y, Mechanick JI, Blonde L, et al, &ldquo;American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan,&rdquo; <i>Endocr Pract</i>, 2011, 17(Suppl 2):1-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/21474420/pubmed\" target=\"_blank\" id=\"21474420\">21474420</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kahn SE, Zinman B, Lachin JM, et al; Diabetes Outcome Progression Trial (ADOPT) study group. Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT). <i>Diabetes Care</i>. 2008;31(5):845-851. doi: 10.2337/dc07-2270.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/18223031/pubmed\" target=\"_blank\" id=\"18223031\">18223031</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaul S, Bolger AF, Herrington D, et al, &quot;Thiazolidinedione Drugs and Cardiovascular Risks: A Science Advisory From the American Heart Association and American College of Cardiology Foundation,&quot; <i>Circulation</i>, 2010, 121(16):1868-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/20179252/pubmed\" target=\"_blank\" id=\"20179252\">20179252</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kirkman M, Briscoe VJ, Clark N, et al, &quot;Diabetes in Older Adults: A Consensus Report,&quot; <i>J Am Geriatr Soc</i>, 2012; doi: 10.1111/jgs.12035.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/23106132/pubmed\" target=\"_blank\" id=\"23106132\">23106132</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kitzmiller JL, Block JM, Brown FM, et al, &quot;Managing Preexisting Diabetes for Pregnancy: Summary of Evidence and Consensus Recommendations for Care,&quot; <i>Diabetes Care</i>, 2008, 31(5):1060-79.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/18445730/pubmed\" target=\"_blank\" id=\"18445730\">18445730</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lago RM, Singh PP, and Nesto RW, &ldquo;Congestive Heart Failure and Cardiovascular Death in Patients with Prediabetes and Type 2 Diabetes Given Thiazolidinediones: A Meta-Analysis of Randomised Clinical Trials,&rdquo; <i>Lancet</i>, 2007, 370 (9593):1129-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/17905165/pubmed\" target=\"_blank\" id=\"17905165\">17905165</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2013;98(12):4565-4592.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/24151290 /pubmed\" target=\"_blank\" id=\"24151290 \">24151290 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lincoff AM, Wolski K, Nicholls SJ, et al, &ldquo;Pioglitazone an Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus,&rdquo; <i>JAMA</i>, 2007, 298(10):1180-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/17848652/pubmed\" target=\"_blank\" id=\"17848652\">17848652</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Metzger BE, Buchanan TA, Coustan DR, et al, &quot;Summary and Recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus,&quot; <i>Diabetes Care</i>, 2007, 30(Suppl 2):S251-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/17596481/pubmed\" target=\"_blank\" id=\"17596481\">17596481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nathan DM, Buse JB, Davidson MB, et al, &ldquo;Medical Management of Hyperglycemia In Type 2 Diabetes: A Consensus Algorithm For The Initiation And Adjustment of Therapy,&rdquo; <i>Diabetes Care</i>, 2009, 32(1):193-203.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/18945920/pubmed\" target=\"_blank\" id=\"18945920\">18945920</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ortega-Gonzalez C, Cardoza L, Coutino B, et al, &quot;Insulin Sensitizing Drugs Increase the Endogenous Dopaminergic Tone in Obese Insulin-Resistant Women With Polycystic Ovary Syndrome,&quot; <i>J Endocrinol</i>, 2005, 184(1):233-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/15642799/pubmed\" target=\"_blank\" id=\"15642799\">15642799</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ota H, Goto T, Yoshioka T, et al, &quot;Successful Pregnancies Treated With Pioglitazone in Infertile Patients With Polycystic Ovary Syndrome,&quot; <i>Fertil Steril</i>, 2008, 90(3):709-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/18423625/pubmed\" target=\"_blank\" id=\"18423625\">18423625</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Practice Committee of American Society for Reproductive Medicine, &quot;Use of Insulin-Sensitizing Agents in the Treatment of Polycystic Ovary Syndrome,&quot; <i>Fertil Steril</i>, 2008, 90(5 Suppl):S69-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/19007650/pubmed\" target=\"_blank\" id=\"19007650\">19007650</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo; <i>Ann Intern Med</i>, 2012, 156(3):218-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/22312141/pubmed\" target=\"_blank\" id=\"22312141\">22312141</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Romualdi D, Guido M, Ciampelli M, et al, &ldquo;Selective Effects of Pioglitazone on Insulin and Androgen Abnormalities in Normo- and Hyperinsulinaemic Obese Patients With Polycystic Ovary Syndrome,&rdquo; <i>Hum Reprod</i>, 2003, 18(6):1210-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/12773448/pubmed\" target=\"_blank\" id=\"12773448\">12773448</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ryden L, Thrainsdottir I, and Swedberg K, &ldquo;Adjudication of Serious Heart Failure in Patients From PROactive,&rdquo; <i>Lancet</i>, 2007, 369(9557):189-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/17240282/pubmed\" target=\"_blank\" id=\"17240282\">17240282</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schwartz AV, Sellmeyer DE, Vittinghoff E, et al, &ldquo;Thiazolidinedione Use and Bone Loss in Older Diabetic Adults,&rdquo; <i>J Clin Endocrin Metab</i>, 2006, 91(9):3349-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/16608888/pubmed\" target=\"_blank\" id=\"16608888\">16608888</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yaturu S, Bryant B, Jain SK, &ldquo;Thiazolidinedione Treatment Decreases Bone Mineral Density in Type 2 Diabetic Men,&rdquo; <i>Diabetes Care</i>, 2007, 30(6):1574-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pioglitazone-drug-information/abstract-text/17363747/pubmed\" target=\"_blank\" id=\"17363747\">17363747</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10216 Version 218.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709212\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F210230\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F50663870\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F210256\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F210234\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F210235\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F210236\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F210237\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F210208\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F210194\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F9350995\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F210210\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F210209\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F210263\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F210201\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F210213\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F210198\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F210250\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F210203\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F210215\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F210216\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F210217\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F210206\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F6258749\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F210197\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F210212\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F210214\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F210218\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10216|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pioglitazone-patient-drug-information\" class=\"drug drug_patient\">Pioglitazone: Patient drug information</a></li></ul></div></div>","javascript":null}